Literature DB >> 6367131

Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay.

D C Rijken, V W van Hinsbergh, E H Sens.   

Abstract

Endothelial cells from human umbilical cord were cultured to study plasminogen activator synthesis and secretion. Since simultaneous production of plasminogen activator inhibitor(s) prevented detection of plasminogen activators by use of fibrinolytic assays, an enzyme immunoassay for tissue-type plasminogen activator (t-PA) was developed. In this assay, t-PA in test samples was adsorbed onto microtiter plates coated with rabbit antibody against t-PA and then quantitated by successive incubation with goat antibody against t-PA and enzyme labeled rabbit antibody against goat IgG. The sensitivity of the assay was found to be 1 ng t-PA/ml. In the absence of serum, arterial and venous endothelial cells continuously produce t-PA antigen during a 24 h period, reaching a level of 5.1 +/- 2.5 ng t-PA/ml (n = 8). In serum containing (20%) medium, 9.3 +/- 6.0 ng t-PA/ml (n = 17) was produced during this period (0.1 - 0.2 ml medium per cm2 confluent cells). It is concluded that the enzyme immunoassay is a useful method for quantitating t-PA secretion by endothelial cells in the presence of proteinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6367131     DOI: 10.1016/0049-3848(84)90175-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  16 in total

1.  Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells.

Authors:  T Kooistra; J van den Berg; A Töns; G Platenburg; D C Rijken; E van den Berg
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

2.  Plasminogen activators in human colorectal neoplasia.

Authors:  J S Gelister; M Mahmoud; M R Lewin; P J Gaffney; P B Boulos
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-20

3.  Quantification of tissue-type plasminogen activator (t-PA) mRNA in human endothelial-cell cultures by hybridization with a t-PA cDNA probe.

Authors:  A J van Zonneveld; G T Chang; J van den Berg; T Kooistra; J H Verheijen; H Pannekoek; C Kluft
Journal:  Biochem J       Date:  1986-04-15       Impact factor: 3.857

4.  Impact of plasminogen on an in vitro wound healing model based on a perfusion cell culture system.

Authors:  Moyuru Hayashi; Yuichi Matsuzaki; Motoyuki Shimonaka
Journal:  Mol Cell Biochem       Date:  2008-11-01       Impact factor: 3.396

5.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

6.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

7.  Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity.

Authors:  Y Sakata; S Curriden; D Lawrence; J H Griffin; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

8.  Gastric mucosal plasminogen activators in Helicobacter pylori infection.

Authors:  J M Götz; Y Vergouwe; H W Verspaget; I Biemond; C F Sier; C B Lamers; R A Veenendaal
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

9.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

Authors:  C F Sier; H W Verspaget; G Griffioen; S Ganesh; H J Vloedgraven; C B Lamers
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

10.  A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney.

Authors:  N Knoers; L A Monnens
Journal:  Eur J Pediatr       Date:  1991-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.